- Home
- DUKRW vs GRI Comparison
DUKRW vs GRI Comparison
Compare DUKRW & GRI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DUKRW | GRI |
|---|---|---|
| Founded | N/A | 2018 |
| Country | Israel | United States |
| Employees | N/A | N/A |
| Industry | Aerospace | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.3M | 3.6M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | DUKRW | GRI |
|---|---|---|
| Price | $1.00 | $1.83 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $160.00 |
| AVG Volume (30 Days) | 14.9K | ★ 97.5K |
| Earning Date | N/A | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.70 | $0.18 |
| 52 Week High | $1.43 | $6.70 |
Technical Indicators
Market Signals| Indicator | DUKRW | GRI |
|---|---|---|
| Relative Strength Index (RSI) | 25.84 | 41.31 |
| Support Level | $0.70 | $1.75 |
| Resistance Level | $1.29 | $1.89 |
| Average True Range (ATR) | 0.14 | 0.14 |
| MACD | -0.04 | -0.01 |
| Stochastic Oscillator | 41.10 | 18.94 |
Price Performance
Historical ComparisonAbout GRI GRI Bio Inc.
GRI Bio Inc is a clinical-stage biotech company focused on discovering, developing, and commercializing therapies targeting serious diseases associated with dysregulated immune responses that to inflammatory, fibrotic, and autoimmune disorders. GRI Bio's program, GRI-0621, is a small molecule RAR-beta and gamma dual agonist that inhibits the activity of human NKT I cells, returning the immune system to homeostasis. It is also an oral formulation of tazarotene, a synthetic RAR-beta and gamma selective agonist for the topical treatment of psoriasis and acne. The company's other product candidate GRI-0803 is a novel oral agonist of type 2 Natural Killer T (type 2 NKT) cells which can be a potential treatment for autoimmune disorders.